- Bristol Myers Squibb ( NYSE: BMY ) is reportedly expected to make antitrust filings to U.S. and German authorities "imminently" for its planned $4.1 billion purchase of Turning Point Therapeutics ( NASDAQ: TPTX ), according to a Dealreporter item.
- The acquisition remains on track for a Q3 closing, according to the report, which cited sources familiar.
- The deal update comes after BMY on Tuesday extended the tender offer for its acquisition of Turning Point Therapeutics ( TPTX ) to Aug. 15.
- BMY agreed to acquire the clinical-stage precision oncology biotech Turning Point ( TPTX ) at a price of $76.00 per share in cash for a total consideration of $4.1B early last month.
For further details see:
Bristol Myers U.S., German antitrust filings for Turning Point expected very soon - report